Hypertension Circulatory System
Conditions
Interventions
The study will enrol hypertensive patients with a left ventricular septum thickness of 13 mm measured with 2D echocardiogram. The overall duration of the study will be of 13 weeks. The first week will
group 2: amlodipine or matching placebo).
After a period of 6 weeks of treatment the first positron emission tomography (PET) scan will be performed.
Afterwards, within each group, patients will c
Sponsors
Abbott (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Blood pressure (measured after 5 minutes in the supine position) 160/100 mmHg based on the mean of 3 recordings within a 1 minute interval 2. Left ventricular septum thickness >=13 mm or left ventricular mass index (LVMI) >=130 g/m2 (men), >=100 g/m2 (women). The measurements will be recorded by echocardiography.
Exclusion criteria
Exclusion criteria: 1. Women of childbearing age without adequate contraception 2. Any documented disease of any of the following systems will be a contraindication to entry into the study: respiratory, renal, digestive, nervous central or peripheral, musculoskeletal, haemolymphopoietic, immune, metabolism 3. Subjects with drug or alcohol addiction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to compare the Coronary Vasodilator Reserve corrected after treatment with verapamil, placebo and amlodipine in hypertensive subjects with left ventricular hypertrophy. With two treatments, two measurements and a within-subject control. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of left ventricular mass | — |
Countries
United Kingdom
Outcome results
None listed